Scancell HoldingsSCNLF 20 3-Year RORE % is -21.82 as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,294 Biotechnology companies, Scancell Holdings ranks worse than 64.91% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Scancell Holdings's 3-Year RORE % for the quarter that ended in Oct. 2025 was -21.82%.
The industry rank for Scancell Holdings's 3-Year RORE % or its related term are showing as below:
SCNLF's 3-Year RORE % is ranked worse than 64.91% of 1294
companies
in the Biotechnology industry
Industry Median: -11.54
vs SCNLF: -21.82
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Scancell Holdings 3-Year RORE % Related Terms
Scancell Holdings 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Scancell Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Oct. 2025 and 3-year before.
Scancell Holdings (SCNLF) has a 3-Year RORE % of -21.82 as of Oct. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #840 out of 1294 companies in the Biotechnology industry, placing it in the top 64.9%.
Is Scancell Holdings' 3-Year RORE % too high?
Scancell Holdings' current 3-Year RORE % is -21.82. Based on the distribution chart, Scancell Holdings ranks #840 out of 1294 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #840 out of 1294 companies for 3-Year RORE %. This places Scancell Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current 3-Year RORE % is -21.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current 3-Year RORE % of -21.82. The current 3-Year RORE % is -21.82. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current 3-Year RORE % is -21.82 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
